Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Backs Approval of Abbott's Humira for New Use

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/28/2012 | 10:06pm CEST

WASHINGTON--A federal advisory panel backed the use of an Abbott Laboratories (>> Abbott Laboratories) drug, Humira, as a treatment for patients with inflammatory bowel disease, saying many patients would benefit from treatment with the product.

Abbott is seeking expanded approval from the U.S. Food and Drug Administration for its anti-inflammatory drug Humira to treat ulcerative colitis. Humira, which had almost $8 billion in annual sales last year, currently is approved to treat rheumatoid arthritis, Crohn's Disease and other inflammatory conditions.

The drug was reviewed Tuesday by the FDA's gastrointestinal drugs advisory committee, which is made up of non-FDA medical experts. The panel voted 15 to 2 on a question that asked whether "the expected benefits outweigh the known and potential risks of Humira" for the treatment of certain patients with ulcerative colitis.

The vote amounts to a recommendation that the FDA approve the product. The FDA usually follows the advice of its panels but is not required to. The FDA declined to approve Humira for colitis last year and asked the company for additional information. The agency also said it would seek the advice of an advisory panel.

Abbott studied Humira in two clinical trials involving more than 1,000 patients. Both studies met goals showing Humira improved rates of disease remission compared to a placebo in people with colitis, an inflammatory bowel disease that causes pain, diarrhea and other symptoms. Patients in the studies also were being treated with older commonly used drugs for colitis including steroids.

Although the FDA agreed that the studies met their goals, the agency questioned whether the difference in remission rates of less than 10% between the Humira groups and placebo groups was "clinically meaningful." The studies showed about 17% to 19% of patients being treated with Humira achieved disease remission at eight weeks compared to about 9% of patients being treated with a placebo, according to the FDA. After one year of treatment the results were similar.

"The central issue is whether the applicant has adequately demonstrated and provided evidence of benefit sufficient to conclude that the benefit outweighs the risks of Humira for [ulcerative colitis]," the FDA said in a background memo prepared for the advisory committee meeting.

However, the majority of the panel disagreed, voting 15 to 1 saying that the differences between the drug and placebo groups were clinically meaningful.

Abbott officials and doctors who spoke on behalf of the company during the panel meeting said many patients with colitis don't respond well to currently available treatments, which also include Johnson & Johnson's (>> Johnson & Johnson) Remicade, and need an additional option. The company proposed stopping treatment in patients who don't respond to the drug after eight weeks of treatment.

Write to Jennifer Corbett Dooren at [email protected]

(CORRECTION: This item was corrected to show that the vote tally was 15 to 2. The original incorrectly stated 12 to 2 in the third paragraph.)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
06/23 ABBOTT LABORATORIES : Federal Contracts Awarded by Federal Agencies in Iowa (Jun..
06/22 ABBOTT LABORATORIES : Patent Issued for Shelf-Stable, Clear Liquid Nutritional C..
06/22 ABBOTT LABORATORIES : Researchers at Abbott Laboratories Target Heart Disease (T..
06/22 ABBOTT LABORATORIES : An Application for the Trademark "THE MARK CONSISTS OF THE..
06/22 ABBOTT LABORATORIES : New Cytokines Findings from Abbott Laboratories Reported (..
06/22 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
06/21 ABBOTT : Hosts Conference Call for Second-Quarter Earnings
06/20 ABBOTT LABORATORIES : Submission of Matters to a Vote of Security Holders (form ..
06/16 ABBOTT LABORATORIES : Broadens Product Offering in Coagulation with Expanded Lau..
06/16 ABBOTT LABORATORIES : Introduces the Alinity hq Hematology Analyzer, the Newest ..
More news
Sector news : Pharmaceuticals - NEC
06:52p UK blue chips led lower by Hargreaves as strong pound takes toll
06:40pDJVECTURA : In Asthma Collaboration With Novartis's Sandoz
05:33pDJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
08:35a Factbox - Companies hit by global ransomware attack on June 27
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/26 BIOTECH BOOM! : Overview And Company-By-Company Review
06/26 Recent Stock Purchase June 2017
06/21 Buying Dividend Growth Stocks Without Looking - More Than 2 Years Later
06/16 RISK ARBITRAGE TODAY : What If Rite Aid Deal Doesn't Happen?
06/15 VIG Never Looked So Dividend-y
Advertisement
Financials ($)
Sales 2017 26 375 M
EBIT 2017 5 725 M
Net income 2017 2 940 M
Debt 2017 15 390 M
Yield 2017 2,22%
P/E ratio 2017 31,75
P/E ratio 2018 24,91
EV / Sales 2017 3,79x
EV / Sales 2018 3,53x
Capitalization 84 456 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 49,3 $
Spread / Average Target 1,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES26.71%84 456
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results